Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Ondexxya
Active substance
andexanet alfa
Therapeutic area (MeSH)
Drug-Related Side Effects and Adverse Reactions
Procedure number
EMEA/H/C/004108/II/0011
Regulatory outcome
Variation
DHPC type
Adverse event
Human ATC code
V03AB
Dissemination date
04/11/2020

How useful was this page?

Add your rating